Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications

Blood

Volumn 92, Issue 3, 1998, Pages 770-777

  Erlanson, Martin ^a   Portin, Cajsa ^a   Linderholm, Barbro ^a   Lindh, Jack ^a   Roos, Göran ^a   Landberg, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PROTEIN P27;

ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC VALUE; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOBLASTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA;

EID: 0032147113     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.3.770.415k37_770_777     Document Type: Article

References (38)

1. Lew DJ, Reed SI: A proliferation of cyclins. Trends Cell Biol 2:77,1992
2. Reed SI: Control of the G1/S transition. Cancer Surv 29:7,1997
3. Elledge S: Cell cycle checkpoints: Preventing an identity crisis. Science 274:1664,1995
4. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1-and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939,1994
5. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387,1995
6. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59,1994
7. Kato JY, Matsuoka M Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487,1994
8. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861,1996
9. Sánchez-Beato M, Saez AI, Martinez-Montero JC, Sol-Mateo M, Sanchez-Verde L, Villuendas R, Troncone G, Pins MA: Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 151:151,1997
10. Motukura T, Arnold A: Cyclins and oncogenesis. Biochim Biophys Acta 1155:63,1993
11. Hirama T, Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841,1995
12. Sherr CJ: Cancer cell cycles. Science 274:1672,1996
13. Ponce-Castañeda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C: p27Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55:1211,1995
14. Nielsen NH, Arnelöv C, Emdin SO, Landberg G: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74:874,1996
15. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222,1997
16. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57:1259,1997
17. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231,1997
18. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381,1997
19. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E: Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88:625,1997
20. Iida H, Towatari M, Tanimoto M, Morishita Y, Kodera Y, Saito H: Overexpression of cyclin E in acute myelogenous leukemia. Blood 90:3707,1997
21. Stansfeld A, Diebold J, Kapanci Y, Kelényi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundström C, van Unnik JAM, Wright DH: Updated Kiel classification for lymphomas. Lancet 1:292, 1988 (letter)
22. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermenlink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke R: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361,1994
23. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA, Armitage JO: Lymphoma classification - The gap between biology and clinical management is closing. Blood 88:4085,1996
24. Vindeløv LL, Christensen IJ, Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323,1983
25. Dutta A, Chandra R, Leiter LM, Lester S: Cyclins as markers of tumor proliferation: Immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA 92:5386,1995
26. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K: Cyclin E, a reductant cyclin in breast cancer. Proc Natl Acad Sci USA 93:15215,1996
27. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP: Deregulation of cyclin E in breast cancer. Oncogene 11:941,1995
28. Wolowiec D, Benchaib M, Pernas P, Deviller P, Soucher C, Rimokh R, Felman P, Bryon PA, Ffrench M: Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue. Leukemia 9:1382,1995
29. Scuderi R, Palucka KA, Pokrovskaja K, Björkholm M, Wiman KG, Pisa P: Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood 87:3360,1996
30. Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermenlink HK, Bentz M, Hiddemann W, Döhner H: Alterations of the cyclin D1/p16-pRb pathway in mantle cell lymphoma. Cancer Res 57:4608,1997
31. Nielsen NH, Emdin SO, Cajander J, Landberg G: Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14:295,1997
32. The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predicitive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987,1993
33. Osterman B, Jonsson H, Tavelin B, Lenner P: Non-Hodgkin's lymphoma in northern Sweden. Prognostic factors and response to treatment. Acta Oncol 32:507,1993
34. Brittinger G, Bartels H, Common H, Dühmke E, Fülle H, Gunzer U, Gyenes T, Heinz R, König E, Meusers P, Paukstat M, Pralle H, Theml H, Köpcke W, Thiemes C, Zwingers T, Musshoss K, Stacher A, Brücker H, Herrman F, Ludwig W, Pribilla W, Burger-Schüller A, Löhr G, Gremmel H, Oertel J, Gerhard H, Koeppen K-M, Boll I, Huhn D, Binder T, Schoengen A, Nowicki L, Pees H, Scheurlen P, Leopold H, Wannenmacher M, Schmidt M, Löffler H, Michlamayr G, Thiel E, Zettel R, Ruhl U, Wilke H, Schwarze E-W, Stein H, Feller A, Lennert K: Clinical and prognostic relevance of the Kiel classification of Non-Hodgkin lymphomas: Results of a prospective multicenter study by the Kiel lymphoma study group. Hematol Oncol 2:269,1984
35. Joensuu H, Ristamäki R, Söderström K-O, Jalkanen S: Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma. J Clin Oncol 12:2167,1994
36. Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 3:227,1997
37. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 11:1204,1996
38. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P: Promoting apoptosis; A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57:5441,1997